Patents by Inventor Barry L. Johnson

Barry L. Johnson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Nonlinear Optical Chromophores Containing Spirofluorene-Isophorone Bridging Groups, and Methods of Making and Using the Same
    Publication number: 20250185503
    Abstract: The present disclosure is directed, in general, to (1) nonlinear optical (NLO) chromophores containing spirofluorene-isophorone bridging groups, including (2) compositions/materials/resistive layers comprising NLO chromophores containing spirofluorene-isophorone bridging groups, and the methods of making the compositions/materials/resistive layers comprising NLO chromophores containing spirofluorene-isophorone bridging groups (e.g., methods of poling and/or drying, and the like), (3) uses of NLO chromophores containing spirofluorene-isophorone bridging groups in electro-optic devices (e.g., EOMs).
    Type: Application
    Filed: December 3, 2024
    Publication date: June 5, 2025
    Applicant: Lightwave Logic, Inc.
    Inventors: Ginelle A. Ramann, Barry L. Johnson
  • Non-Linear Optical Chromophores with Michler's Base-Type Donors
    Publication number: 20250019589
    Abstract: The present invention is directed, in general, to nonlinear optical chromophores having a Michler's base-type group. Various embodiments of the present invention include nonlinear optical chromophores with Michler's base-type group having a Michler's base donor group connected to a ?-bridge group. Various embodiments of the present invention include nonlinear optical chromophores with Michler's base-type group having high photostability, which chromophores can reduce the percentage of being deactivated by molecular oxygen under illumination.
    Type: Application
    Filed: July 2, 2024
    Publication date: January 16, 2025
    Applicant: Lightwave Logic, Inc.
    Inventors: Ginelle A. Ramann, Barry L. Johnson, Cory Pecinovsky
  • Nonlinear Optical Chromophores with Indolizine Donor Groups
    Publication number: 20250011321
    Abstract: The present invention is directed, in general, to nonlinear optical chromophores having an indolizine donor group. Various embodiments of the present invention include nonlinear optical chromophores with indolizine donor group having an indolizine donor connected to a II-bridge group. In various preferred embodiments of the present invention, the indolizine donor groups may be substituted or unsubstituted, including hydro and alkyl substituents, aryl substituents and combination thereof. In certain embodiments of the present invention, the substituent moieties in the indolizine donor groups may be important for isolation. The isolation may reduce chromophore-chromophore interaction. The isolation may reduce charge transfer between molecules. The isolation may increase maximum applied voltage, which may contribute to more optimal poling and higher r33.
    Type: Application
    Filed: June 27, 2024
    Publication date: January 9, 2025
    Applicant: Lightwave Logic, Inc.
    Inventors: Ginelle A. Ramann, Barry L. Johnson, Cory Pecinovsky
  • 2-keto amide derivatives as HIV attachment inhibitors
    Patent number: 9586957
    Abstract: Compounds of Formula I, including pharmaceutically acceptable salts thereof: I useful as HIV attachment inhibitors.
    Type: Grant
    Filed: March 25, 2014
    Date of Patent: March 7, 2017
    Assignee: ViiV Healthcare UK (No.5) Limited
    Inventors: Tao Wang, Zhiwei Yin, Zhongxing Zhang, John A. Bender, Barry L. Johnson, John F. Kadow, Nicholas A. Meanwell
  • Piperidine amide derivatives as HIV attachment inhibitors
    Patent number: 9505752
    Abstract: Compounds of Formula I, including pharmaceutically acceptable salts thereof: formula (I): wherein A is selected from the group consisting of: formula (II) and wherein Z is selected from the group consisting of: formula (III): and. are useful as HIV attachment inhibitors.
    Type: Grant
    Filed: August 7, 2013
    Date of Patent: November 29, 2016
    Assignee: ViiV Healthcare UK (No. 5) Limited
    Inventors: Tao Wang, Zhongxing Zhang, John F. Kadow, Nicholas A. Meanwell, Edward H. Ruediger, Clint A. James, Daniel H. Deon, David J. Carini, Barry L. Johnson
  • 2-KETO AMIDE DERIVATIVES AS HIV ATTACHMENT INHIBITORS
    Publication number: 20160052924
    Abstract: Compounds of Formula I, including pharmaceutically acceptable salts thereof: I useful as HIV attachment inhibitors.
    Type: Application
    Filed: March 25, 2014
    Publication date: February 25, 2016
    Inventors: Tao Wang, Zhiwei Yin, Zhongxing Madison, John A. Bender, Barry L. Johnson, Jhon F. Kadow, Nicholas A. Meanwell
  • PIPERAZINE AND HOMOPIPERAZINE DERIVATIVES AS HIV ATTACHMENT INHIBITORS
    Publication number: 20160052923
    Abstract: Compounds of Formula I, including pharmaceutically acceptable salts thereof, are useful as HIV attachment inhibitors.
    Type: Application
    Filed: March 25, 2014
    Publication date: February 25, 2016
    Inventors: Tao Wang, Zhiwei Yin, Zhongxing Zhang, Barry L. Johnson, John F. Kadow, Nicholas A. Meanwell
  • PIPERIDINE AMIDE DERIVATIVES AS HIV ATTACHMENT INHIBITORS
    Publication number: 20150210684
    Abstract: Compounds of Formula I, including pharmaceutically acceptable salts thereof: formule (I): wherein A is selected from the group consisting of: formule (II) and wherein Z is selected from the group consisting of: formule (III): and. are useful as HIV attachment inhibitors.
    Type: Application
    Filed: August 7, 2013
    Publication date: July 30, 2015
    Inventors: Tao Wang, Zhongxing Zhang, John F. Kadow, Nicholas A. Meanwell, Edward H. Ruediger, Clint A. James, Daniel H. Deon, David J. Carini, Barry L. Johnson
  • HIV integrase inhibitors
    Patent number: 8835411
    Abstract: The disclosure generally relates to the novel compounds of formula I, including their salts, which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.
    Type: Grant
    Filed: December 6, 2011
    Date of Patent: September 16, 2014
    Assignee: Bristol-Myers Squibb Company
    Inventors: Yasutsuga Ueda, Timothy P. Connolly, Barry L. Johnson, Chen Li, B. Narasimhulu Naidu, Manoj Patel, Kevin Peese, Margaret E. Sorenson, Michael A. Walker, Michael S. Bowsher, Rongti Li
  • Inhibitors of human immunodeficiency virus replication
    Patent number: 8629276
    Abstract: The disclosure generally relates to compounds of formula I, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection.
    Type: Grant
    Filed: February 13, 2013
    Date of Patent: January 14, 2014
    Assignee: Bristol-Myers Squibb Company
    Inventors: Michael A. Walker, Margaret E. Sorenson, B. Narasimhulu Naidu, Kevin Peese, Barry L. Johnson, Manoj Patel
  • HIV Integrase Inhibitors
    Publication number: 20120309698
    Abstract: The disclosure generally relates to the novel compounds of formula I, including their salts, which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.
    Type: Application
    Filed: December 6, 2011
    Publication date: December 6, 2012
    Inventors: Yasutsugu Ueda, Timothy P. Connolly, Barry L. Johnson, Chen Li, B. Narasimhulu Naidu, Manoj Patel, Kevin Peese, Margaret E. Sorenson, Michael A. Walker, Michael S. Bowsher, Rongti Li
  • Diketo substituted pyrrolo[2,3-C]pyridines
    Patent number: 8124615
    Abstract: Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, diketo fused azolopiperidine and azolopiperazine derivatives of Formula I: that possess unique antiviral activity are provided. These compounds are useful for the treatment of HIV and AIDS.
    Type: Grant
    Filed: May 5, 2011
    Date of Patent: February 28, 2012
    Assignee: Bristol-Myers Squibb Company
    Inventors: Tao Wang, Yasutsugu Ueda, Lawrence G. Hamann, Zhongxing Zhang, Zhiwei Yin, Alicia Regueiro-Ren, David J. Carini, Jacob Swidorski, Zheng Liu, Barry L. Johnson, Nicolas A. Meanwell, John F. Kadow
  • DIKETO FUSED AZOLOPIPERIDINES AND AZOLOPIPERAZINES AS ANTI-HIV AGENTS
    Publication number: 20110212971
    Abstract: Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, diketo fused azolopiperidine and azolopiperazine derivatives that possess unique antiviral activity are provided. These compounds are useful for the treatment of HIV and AIDS.
    Type: Application
    Filed: May 5, 2011
    Publication date: September 1, 2011
    Inventors: Tao Wang, Yasutsugu Ueda, Lawrence G. Hamann, Zhongxing Zhang, Zhiwei Yin, Alicia Regueiro-Ren, David J. Carini, Jacob Swidorski, Zheng Liu, Nicolas A. Meanwell, John F. Kadow, Barry L. Johnson
  • Diketo substituted pyrrolo[2,3-c] pyridines
    Patent number: 7960406
    Abstract: Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, diketo fused azolopiperidine and azolopiperazine derivatives of Formula I: that possess unique antiviral activity are provided. These compounds are useful for the treatment of HIV and AIDS.
    Type: Grant
    Filed: June 24, 2009
    Date of Patent: June 14, 2011
    Assignee: Bristol-Myers Squibb Company
    Inventors: Tao Wang, Yasutsugu Ueda, Lawrence G. Hamann, Zhongxing Zhang, Zhiwei Yin, Alicia Regueiro-Ren, David J. Carini, Jacob Swidorski, Zheng Liu, Barry L. Johnson, Nicholas A. Meanwell, John F. Kadow
  • Hepatitis C virus inhibitors
    Patent number: 7772183
    Abstract: Hepatitis C virus inhibitors having the general formula are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
    Type: Grant
    Filed: October 11, 2006
    Date of Patent: August 10, 2010
    Assignee: Bristol-Myers Squibb Company
    Inventors: David J. Carini, Barry L. Johnson, Zhizhen Barbara Zheng, Stanley D'Andrea, Paul Michael Scola
  • Diketo Fused Azolopiperidines and Azolopiperazines as Anti-HIV Agents
    Publication number: 20100009993
    Abstract: Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, diketo fused azolopiperidine and azolopiperazine derivatives that possess unique antiviral activity are provided. These compounds are useful for the treatment of HIV and AIDS.
    Type: Application
    Filed: June 24, 2009
    Publication date: January 14, 2010
    Inventors: Tao Wang, Yasutsugu Ueda, Lawrence G. Hamann, Zhongxing Zhang, Zhiwei Yin, Alicia Regueiro-Ren, David J. Carini, Jacob Swidorski, Zheng Liu, Nicholas A. Meanwell, John F. Kadow, Barry L. Johnson
  • Macrocyclic isoquinoline peptide inhibitors of hepatitis C virus
    Patent number: 7173004
    Abstract: Macrocyclic isoquinoline peptides are disclosed having the general formula: A compound of formula I: wherein R1 to R9, Q and W are described in the description. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
    Type: Grant
    Filed: April 16, 2004
    Date of Patent: February 6, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: Fiona McPhee, Jeffrey Allen Campbell, Stanley D'Andrea, Zhizhen Barbara Zheng, Andrew Charles Good, David J. Carini, Barry L. Johnson, Paul Michael Scola, Kenneth M. Boy
  • Tricyclic compounds useful as HIV reverse transcriptase inhibitors
    Patent number: 6825210
    Abstract: The present invention relates to tricyclic compounds of formula (I): or stereoisomeric forms, stereoisomeric mixtures, or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of HIV reverse transcriptase, and to pharmaceutical compositions and diagnostic kits comprising the same, and methods of using the same for treating viral infection or as an assay standard or reagent.
    Type: Grant
    Filed: April 17, 2002
    Date of Patent: November 30, 2004
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Barry L. Johnson, James D. Rodgers, Qiyan Lin, Anurag S. Srivastava
  • Tricyclic compounds useful as HIV reverse transcriptase inhibitors
    Publication number: 20040002498
    Abstract: The present invention relates to tricyclic compounds of formula (I): 1
    Type: Application
    Filed: April 24, 2003
    Publication date: January 1, 2004
    Inventors: Barry L. Johnson, Mona Patel, James D. Rodgers, Haisheng Wang, Christine M. Tarby, Rajagopal Bakthavatchalam
  • Tricyclic compounds useful as HIV reverse transcriptase inhibitors
    Patent number: 6593337
    Abstract: The present invention relates to tricyclic compounds of formula (I): or stereoisomeric forms, stereoisomeric mixtures, or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of HIV reverse transcriptase, and to pharmaceutical compositions and diagnostic kits comprising the same, and methods of using the same for treating viral infection or as an assay standard or reagent.
    Type: Grant
    Filed: October 18, 2000
    Date of Patent: July 15, 2003
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Barry L. Johnson, Mona Patel, James D. Rodgers, Christine M. Tarby, Rajagopal Bakthavatchalam